Question 1

What are the potential side effects of the aQIVc vaccine?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older clinical trial (NCT06015282). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the aQIVc vaccine compare to other flu vaccines I may have received?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older clinical trial (NCT06015282). Contact the study team or your healthcare provider for specific answers.

Question 3

What will happen during the study visits?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older clinical trial (NCT06015282). Contact the study team or your healthcare provider for specific answers.

Question 4

How long will I need to participate in the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older clinical trial (NCT06015282). Contact the study team or your healthcare provider for specific answers.

Question 5

Are there any costs associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older clinical trial (NCT06015282). Contact the study team or your healthcare provider for specific answers.

Question 6

What kind of follow-up care will I receive after the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older clinical trial (NCT06015282). Contact the study team or your healthcare provider for specific answers.

What this study is about